ArticleJournal of acquired immune deficiency syndromes (1999)2011
The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone.
Article in Journal of acquired immune deficiency syndromes (1999), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00263458 (Integrating Buprenorphine Into the SFGH AIDS Program), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Integrating Buprenorphine Into the SFGH AIDS Program (Patient Evaluation Study)
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Representation of women and pregnant women in HIV research: a limited systematic review.PloS one · 2013Pooled it
- Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system.Drug and alcohol dependence · 2015Trial
- Retention in methadone and buprenorphine treatment among African Americans.Journal of substance abuse treatment · 2013Trial
- Joint effects of substance use disorders and recent substance use on HIV viral non-suppression among people engaged in HIV care in an urban clinic, 2014-2019.Addiction (Abingdon, England) · 2023Article
- Changes in substance use in relation to opioid agonist therapy among people who use drugs in a Canadian setting.Drug and alcohol dependence · 2020Article
- Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco.Addiction science & clinical practice · 2019Article
- Opioid and cocaine use among primary care patients on buprenorphine-Self-report and urine drug tests.Drug and alcohol dependence · 2018Article
- Opioids and HIV Infection: From Pain Management to Addiction Treatment.Topics in antiviral medicine · 2018Article
- Primary Care-Based Models for the Treatment of Opioid Use Disorder: A Scoping Review.Annals of internal medicine · 2017Article
- Methadone maintenance therapy and viral suppression among HIV-infected opioid users: The impacts of crack and injection cocaine use.Drug and alcohol dependence · 2016Article
- A Remotely-Delivered CBT and Contingency Management Therapy for Substance Using People with HIV.AIDS and behavior · 2015Article
- Substance use in older HIV-infected patients.Current opinion in HIV and AIDS · 2014Review
- Clinically relevant characteristics associated with early treatment drug use versus abstinence.Addiction science & clinical practice · 2014Article
- Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes.Drug and alcohol dependence · 2013Article
- Article
- Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users.The American journal on addictionsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundCocaine use is common in opioid-dependent HIV-infected patients, but its impact on treatment outcomes in these patients receiving buprenorphine/naloxone is not known.
methodsWe conducted a prospective study in 299 patients receiving buprenorphine/naloxone who provided baseline cocaine data and a subset of 266 patients who remained in treatment for greater than or equal to one quarter. Assessments were conducted at baseline and quarterly for 1 year. We evaluated the association between baseline and in-treatment cocaine use on buprenorphine/naloxone retention, illicit opioid use, antiretroviral adherence, CD4 counts, HIV RNA, and risk behaviors.
resultsSixty-six percent (197 of 299) of patients reported baseline cocaine use and 65% (173 of 266) of patients with follow-up data reported in-treatment cocaine use. Baseline and in-treatment cocaine use did not impact buprenorphine/naloxone retention, antiretroviral adherence, CD4 lymphocytes, or HIV risk behaviors. However, baseline cocaine use was associated with a 14.8 (95% confidence interval [CI], 9.0-24.2) times greater likelihood of subsequent cocaine use (95% CI, 9.0-24.2), a 1.4 (95% CI, 1.02-2.00) times greater likelihood of subsequent opioid use, and higher log10 HIV RNA (P < 0.016) over time. In-treatment cocaine use was associated with a 1.4 (95% CI, 1.01-2.00) times greater likelihood of concurrent opioid use.
conclusionsGiven cocaine use negatively impacts opioid and HIV treatment outcomes, interventions to address cocaine use in HIV-infected patients receiving buprenorphine/naloxone treatment are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.